Fibrinolytic therapy in coronary artery disease.
Gill
J B
JB
Massel
D
D
Cairns
J
J
D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use; D001315:Australia / Q000453:epidemiology; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005060:Europe / Q000453:epidemiology; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006474:Hemorrhagic Disorders / Q000139:chemically induced; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D015425:Myocardial Reperfusion; D009520:New Zealand / Q000453:epidemiology; D009656:North America / Q000453:epidemiology; D010960:Plasminogen Activators / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D012008:Recurrence; D013300:Streptokinase / Q000627:therapeutic use; D013318:Stroke Volume / Q000187:drug effects; D015912:Thrombolytic Therapy
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D013300:Streptokinase; D010960:Plasminogen Activators